Key Performance
More- Earnings Score: N/A
- Momentum Score: 39
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
The global scar treatment market is projected to grow from USD 26.60 billion in 2025 to USD 56.30 billion by 2033, with a CAGR of 9.91%. Growth is driven by increasing awareness of advanced cosmetic and reconstructive procedures, rising prevalence of acne, surgical, and traumatic scars, and technological advancements in minimally invasive treatments. The U.S. market alone is expected to reach USD 17.69 billion by 2033.
02/18/2026, 4:00 AM • GlobeNewswire
AVITA Medical presented 19 scientific abstracts at the 2026 Boswick Burn & Wound Symposium, including the first surgeon-reported integrated use of its three technologies (RECELL, PermeaDerm, and Cohealyx) in patient cases. New clinical and histological data demonstrated that RECELL use was associated with smaller donor sites, faster healing times, improved pain and appearance outcomes, and more favorable health economics. Real-world studies showed RECELL reduced hospital stays by up to 36% in deep partial-thickness burns and nearly 16 days shorter stays in elderly burn patients.
01/25/2026, 5:30 PM • GlobeNewswire
Law firm Bragar Eagel & Squire is investigating potential securities violations at three companies: Soleno Therapeutics following a report questioning its product's safety and pricing, AVITA Medical due to significant claim payment backlogs affecting product utilization, and Coty following unexpected losses and disappointing guidance attributed to market challenges.
01/08/2026, 5:00 PM • GlobeNewswire
AVITA Medical Announces CEO Transition
AVITA Medical announced Cary Vance as Interim CEO, replacing Jim Corbett. The company expects Q3 2025 revenue of approximately $17 million and is seeking a permanent CEO through an executive search.
10/16/2025, 6:15 PM • GlobeNewswire
Law firm investigating potential claims against AVITA Medical after company reported significant backlog of unpaid provider claims for Recell procedures, causing stock price to decline by 21%.
10/16/2025, 5:43 PM • GlobeNewswire
Law firm investigating potential securities law violations by Marex Group after a research report alleging accounting irregularities caused stock price decline.
10/09/2025, 1:00 PM • GlobeNewswire
Bragar Eagel & Squire is investigating potential claims against AVITA Medical after the company reported a six-month backlog in unpaid provider claims for Recell procedures, which caused a 21% stock price decline.
10/09/2025, 12:49 PM • GlobeNewswire
AVITA Medical reported a six-month backlog in unpaid provider claims for Recell procedures, causing uncertainty among providers and leading to reduced product utilization, which resulted in a 21% stock price drop.
09/29/2025, 8:45 PM • GlobeNewswire
AVITA Medical experienced significant stock decline after revealing a six-month backlog in unpaid provider claims for Recell procedures, caused by Medicare & Medicaid Services' pricing and claims adjudication issues.
09/15/2025, 5:45 PM • GlobeNewswire
AVITA Medical Receives CE Mark for RECELL® GO, Enabling Commercialization Across Europe
AVITA Medical received CE Mark for RECELL GO, a point-of-care device that prepares a patient's skin cells to promote healing in burns and wounds. Clinical data shows the technology reduces hospital stays by 36% compared to traditional grafting methods.
09/14/2025, 7:00 PM • GlobeNewswire
Pomerantz Law Firm is investigating potential securities fraud at AVITA Medical after the company reported a six-month backlog in unpaid provider claims for Recell procedures, which led to a 21% stock price drop.
09/10/2025, 2:51 PM • GlobeNewswire
AVITA Medical, Inc. Investors: Company Investigated by the Portnoy Law Firm
AVITA Medical experienced significant share price decline after reporting a six-month backlog in unpaid provider claims for Recell procedures, caused by Medicare & Medicaid Services contractors' delays in claim pricing and adjudication.
09/09/2025, 3:47 PM • GlobeNewswire
AVITA Medical reported a six-month backlog in unpaid provider claims for Recell procedures, causing uncertainty among providers and reducing product utilization, which led to a 21% stock price drop.
09/04/2025, 11:00 AM • GlobeNewswire
AVITA Medical experienced significant stock price decline after revealing a six-month backlog in unpaid provider claims for Recell procedures, which created uncertainty among healthcare providers and reduced product utilization.
09/03/2025, 5:00 PM • GlobeNewswire
AVITA Medical, Inc. Investors: Company Investigated by the Portnoy Law Firm
AVITA Medical experienced significant stock price decline after reporting a six-month backlog in unpaid provider claims for its Recell wound care product, caused by Medicare & Medicaid Services contractor delays in claim processing.
08/28/2025, 3:41 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/02/2026
Company Profile
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company sells and distributes PermeaDerm, a biosynthetic wound matrix and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.